Adverse Event Clinical Trial
— PREDICTOfficial title:
Impact of an Epic-integrated Safety Dashboard and Interactive Pre-discharge Checklist on Post-discharge Adverse Events
Verified date | January 2022 |
Source | Brigham and Women's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to expand the use of previously developed patient safety dashboards and patient-centered discharge checklists to three general medicine units in an affiliated community hospital. The safety dashboard and interactive pre-discharge checklist are cognitive aids for clinicians and patients, respectively, that serve to facilitate early detection of patients at risk for preventable harm, including suboptimal discharge preparation. The aims of this study are to: 1. Enhance the safety dashboard and interactive pre-discharge checklist to include "smart" notifications for hospital-based clinicians when patients are at high risk for adverse events or have identified specific concerns related to discharge based on their checklist responses. 2. Expand intervention to general medical units at our community hospital-affiliate, BWFH. 3. Evaluate impact on post-discharge AEs for patients discharged from BWFH who are at risk for preventable harm and hospital readmission.
Status | Completed |
Enrollment | 268 |
Est. completion date | September 30, 2020 |
Est. primary completion date | March 20, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female, >18 years of age, English-speaking - Caregivers >18 years of age designated by patient or patient's healthcare proxy - Two or more patient safety risk factors Exclusion Criteria: - Non-English speaking patients for whom we cannot identify an English-speaking healthcare proxy |
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Women's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Brigham and Women's Hospital | Crico |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Potential Post-Discharge Adverse Events | Potential post-discharge adverse events will be measured as the number of new or worsening symptoms or signs per patient | 24 months | |
Secondary | Actual Post-Discharge Adverse Events | Actual post-discharge adverse events will be measured as the number of adverse events per patient | 24 months | |
Secondary | Preventable Post-Discharge Adverse Events | Actual post-discharge adverse events related to preventable harm will be measured as the number of post-discharge adverse events per patient related to a specific safety risk domain identified during index hospitalization | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Completed |
NCT03482232 -
Consequences of Doing What Should Not be Done in Primary Care
|
||
Completed |
NCT05693051 -
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
|
||
Completed |
NCT04055363 -
Human Milk Oligosaccharides (HMOs) Post-market Study on Infants
|
N/A | |
Completed |
NCT05133817 -
Prophylactic Norepinephrine Infusion Combined With Colloid Coloading for Postspinal Anesthesia Hypotension
|
N/A | |
Completed |
NCT02996201 -
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT05462938 -
Conscious Sedation for Transcatheter Aortic Valve Implantation
|
N/A | |
Completed |
NCT04562922 -
LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy
|
Phase 2 | |
Recruiting |
NCT03740464 -
Long-acting G-CSF for Febrile Neutropenia
|
Phase 3 | |
Completed |
NCT03332433 -
High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol
|
N/A | |
Not yet recruiting |
NCT04615156 -
18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
|
Phase 3 | |
Recruiting |
NCT03381534 -
Safety and Efficacy of Distal Embolic Protection Device in Vertebral Artery Origin Stenting
|
N/A | |
Completed |
NCT04570488 -
Predicting Favorable Outcomes in Hospitalized Covid-19 Patients
|
||
Recruiting |
NCT05369962 -
Adverse Event Prediction in Geriatric Patients in the ED With Ultrasound
|
||
Completed |
NCT05321160 -
Comparison of the Sedation Effect of Esketamine and Sevoflurane for Pediatric Ophthalmological Procedure
|
N/A | |
Withdrawn |
NCT03673566 -
Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO
|
N/A | |
Completed |
NCT03745677 -
Redesigning Systems to Improve Quality for Hospitalized Patients
|
N/A | |
Completed |
NCT04763876 -
Intramuscular Ketorolac at Two Single-Dose Regimens
|
Phase 4 | |
Withdrawn |
NCT03673579 -
Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB
|
N/A | |
Enrolling by invitation |
NCT05443217 -
Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments
|